AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Artelo Biosciences, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00793XCX9
2.55▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
2.55
Day's Range
2.48 – 2.66
52-Week Range
0.52 – 19.91
Volume
26.0K
Avg Volume
903.9K
Share Statistics
Shares Outstanding
Employees
7
Exchange
XNAS
Listed
2015-10-13
Share count as of August 11, 2026

Artelo Biosciences, Inc. Common Stock (ARTL) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Artelo Biosciences, Inc. Common Stock (ARTL)
What is Artelo Biosciences, Inc. Common Stock's Market Cap?
Artelo Biosciences, Inc. Common Stock's Market Cap is $11.7M, based on as-reported figures from SEC (XBRL) filings.
What is Artelo Biosciences, Inc. Common Stock's Enterprise Value?
Artelo Biosciences, Inc. Common Stock's Enterprise Value is $7.5M, based on as-reported figures from SEC (XBRL) filings.
What is Artelo Biosciences, Inc. Common Stock's Net Income (TTM)?
Artelo Biosciences, Inc. Common Stock's Net Income (TTM) is -$12.7M, based on as-reported figures from SEC (XBRL) filings.
What is Artelo Biosciences, Inc. Common Stock's Diluted EPS (TTM)?
Artelo Biosciences, Inc. Common Stock's Diluted EPS (TTM) is -2.76, based on as-reported figures from SEC (XBRL) filings.
What is Artelo Biosciences, Inc. Common Stock's Net Debt?
Artelo Biosciences, Inc. Common Stock's Net Debt is -$4.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ARTLAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
OPERATING EXPENSES
Selling, General and Administrative Expense
Research and Development Expense
Total Operating Expenses
Loss from Operations
OTHER INCOME (EXPENSE)
Interest Income—
Interest expense
Interest expense - related party——
Non-Operating Income (Expense)
Total other income (expense)
Income Tax Expense—
NET LOSS
Earnings Per Share (Diluted)—